Wu Baojian, Deng Daoyin, Lu Yi, Wu Wei
Department of Pharmaceutics, Fudan University, Shanghai, PR China.
Eur J Pharm Biopharm. 2008 May;69(1):294-302. doi: 10.1016/j.ejpb.2007.10.001. Epub 2007 Oct 5.
The pectin/calcium interaction, which is the basis for biphasic release of indomethacin from the HPMC/pectin/calcium chloride matrix tablet, is susceptible to influence of a variety of variables that is supposed to be encountered by the oral route. In this study, the effect of influencing variables on biphasic release characteristics, the stability and the pharmacokinetics of the hybrid matrix tablet were investigated. An increasing tendency of the overall release rate was observed from pH 1.2 to 7.4. The power law correlation n values increased with pH, while the release lag time or 10% release time (T0.1) decreased at pH 6.8 and 7.4. Ionic strength in the release media also influenced the biphasic release significantly at sodium chloride levels of over 0.5%. Obvious increase in overall release rate was observed at sodium chloride level of 0.9% with an n value of 1.20 and a T0.1 of 3.4h. At sodium chloride levels of over 2%, the pectin/calcium interaction was disrupted resulting in very fast release of indomethacin. Release in gradient pH media was similar to that in pH 6.8 citrate buffer. When pectinase (Pectinex Ultra SP-L) was added into the release medium in 22.2 pg/ml or over, obvious triggering on drug release was observed. The stress testing showed increased release at extreme relative humidity of 92.5%. Both accelerated testing for 6m and long-term testing for 12 m affirmed fine stability, especially in release characteristics. Pharmacokinetic study in dogs gave Tmax/Cmax of 4h/604 ng/ml and 3h/1662 ng/ml for HPMC/pectin/calcium and HPMC/pectin tablet, respectively. The plasma indomethacin level of the calcium-containing tablet was maintained at a much lower level for 3h with a MRT of 7.13 h, longer than 3.97 and 5.61 h for indomethacin crude drug and HPMC/pectin tablet, confirming delayed absorption. The AUC of the HPMC/pectin/calcium tablet was lower than that of the HPMC/pectin tablet and indomethacin crude drug showing incomplete absorption. It is concluded that the HPMC/pectin/calcium matrix tablet is potentially useful for colon-specific drug delivery.
果胶/钙相互作用是吲哚美辛从羟丙甲纤维素/果胶/氯化钙骨架片中双相释放的基础,易受口服途径中各种可变因素的影响。在本研究中,考察了影响因素对混合骨架片双相释放特性、稳定性及药代动力学的影响。从pH 1.2到7.4观察到总体释放速率呈增加趋势。幂律相关性n值随pH升高而增加,而在pH 6.8和7.4时释放滞后时间或10%释放时间(T0.1)缩短。释放介质中的离子强度在氯化钠浓度超过0.5%时也对双相释放有显著影响。在氯化钠浓度为0.9%时观察到总体释放速率明显增加,n值为1.20,T0.1为3.4小时。在氯化钠浓度超过2%时,果胶/钙相互作用被破坏,导致吲哚美辛快速释放。在梯度pH介质中的释放与在pH 6.8柠檬酸盐缓冲液中的释放相似。当果胶酶(Pectinex Ultra SP-L)以22.2 pg/ml或更高浓度加入释放介质中时,观察到对药物释放有明显的触发作用。加速试验6个月和长期试验12个月均证实稳定性良好,尤其是在释放特性方面。犬的药代动力学研究表明,羟丙甲纤维素/果胶/钙片和羟丙甲纤维素/果胶片的Tmax/Cmax分别为4小时/604 ng/ml和3小时/1662 ng/ml。含钙片剂的血浆吲哚美辛水平在3小时内维持在低得多的水平,平均滞留时间为7.13小时,长于吲哚美辛原料药和羟丙甲纤维素/果胶片的3.97小时和5.61小时,证实吸收延迟。羟丙甲纤维素/果胶/钙片剂的AUC低于羟丙甲纤维素/果胶片和吲哚美辛原料药,表明吸收不完全。结论是羟丙甲纤维素/果胶/钙骨架片对结肠特异性给药有潜在应用价值。